SynthesisClinical and experimental medicine2025
Management and outcomes of solid pseudopapillary neoplasm of the pancreas: a systematic review.
Synthesis in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Article
- Article
- Development and validation of a nomogram for overall survival in pancreatic solid pseudopapillary neoplasm: a population-based study.Scientific reports · 2026Article
- Small Hepatoid Variant of Solid Pseudopapillary Neoplasm of the Pancreas: A Unique Case With Long-term Follow-up.DEN open · 2026Article
- Case Report: Delayed diagnosis of pancreatic solid pseudopapillary neoplasm in a boy initially misdiagnosed as traumatic retroperitoneal hematoma.Frontiers in pediatrics · 2026Article
- Retroperitoneal paraganglioma mimicking a solid pseudopapillary neoplasm of the pancreatic tail and confirmed by percutaneous biopsy: a case report.Frontiers in oncology · 2026Article
- Surgical and functional outcomes of pediatric pancreatic solid pseudopapillary neoplasm: A retrospective study.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Solid pseudopapillary neoplasm of the pancreas (SPN-P) is a rare entity, accounting for about 0.9-2.7% of all exocrine and 5% of cystic pancreatic neoplasms. There is limited evidence on the clinical, surgical, and oncological characteristics of SPN-P, as well as surgical short- and long-term outcomes. A systematic review was conducted searching four databases (MEDLINE/PubMed, Web of Science, Scopus and Cochrane Library) from January 2004 to August 2024, adhering to the reporting standards for systematic reviews. Eligible studies of provided information on key clinical features of SPN-P, surgical management, and surgical and oncological outcomes were reviewed. A total of 1315 studies were identified, of which 54 met the inclusion criteria. Data from 1.888 SPN-P patients, comprising 1.617 women (85.6%) and 271 men (14.4%), with a mean age of 30, 7 years (range: 7-87 years) were collected. Of these patients, 1.882 underwent surgical intervention, and 1.869 received pancreatic resection. The most common postoperative complication was postoperative pancreatic fistula, which was more prevalent in cases of parenchyma-preserving surgery (23%). Other complications included wound infections, intra-abdominal collections, delayed gastric emptying, and pancreatic insufficiency. Surgical intervention remains the gold standard for the treatment of SPN-P, offering favourable oncological outcomes and an excellent prognosis. Nonetheless, further research is required to address unresolved aspects of SPN-P surgical management and optimize treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.